Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of the serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary…
A study recently published in the journal European Respiratory Review reported the case of a man with pulmonary hypertension resulting from silica exposure-induced sarcoidosis. The report urges clinicians to be aware of this rare cause of pulmonary hypertension, in which specific analyses are needed to confirm a diagnosis.
Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of a serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM…
The following are the 5 different classes of pulmonary hypertension. For a detailed overview of each class, click on the link: Arterial PH: Pulmonary arterial hypertension (PAH) involves abnormally high blood pressure (hypertension) in the pulmonary artery. Venous PH: Pulmonary venous hypertension (PVH) differs from…
German researchers evaluating a possible new biomarker for pulmonary arterial hypertension (PAH) found that the molecule, known as chemokine CXC ligand 13 (CXCL13), was higher in the blood serum and lung tissue of people with PAH — suggesting a pathogenic role but one short of serving as a disease marker. The report,…
Recent advances made, and insights gained, in clinical and preclinical research into pulmonary hypertension were highlighted in a Clinical Year in Review article published in the journal European Respiratory Review. The article, “Pulmonary hypertension,” offers hope that pulmonary hypertension might become a well-managed, and potentially even…
German President Joachim Gauck has awarded the 2015 Deutscher Zukunftspreis, which honors innovation in science and technology, to a pulmonary hypertension (PH) research team that discovered and developed a drug effective in the treatment of two serious types of the disease. The winning team — led by Professor Ardeschir Ghofrani from the University Clinic…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a rare, life-threatening condition characterized by high blood pressure in the lungs and measured according to a resting mean pulmonary arterial pressure of 25 mmHg or greater at right heart catheterization. The disease is associated with damage to the pulmonary arteries, which are responsible for transporting blood…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a severe disease diagnosed when the arteries responsible for transporting blood from the heart to the lungs become constricted. Under normal circumstances, blood is supposed to gather oxygen from the lungs and distribute it to the organs, muscles and body tissue. However, due to the disease, normal blood flow…
Pulmonary hypertension is a chronic and progressive disease characterized by high blood pressure in the pulmonary arteries, the blood vessels of the lungs. There are many potential causes of the disease that, along with how early the disease is diagnosed and when treatment…
Ventavis (iloprost) is an approved therapy for improving the exercise capacity of people with pulmonary arterial hypertension (PAH), and potentially delaying or reducing the worsening of the disease. Ventavis was developed by Schering AG but is now marketed by Bayer in Europe…
The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…
Get regular updates to your inbox.
